Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®

Rhea-AI Summary

Ascendis (Nasdaq: ASND) has been added to multiple Russell U.S. indexes, including the Russell 3000, Russell 1000, Russell 2500 and Russell Midcap, effective after the U.S. market close on June 26, 2026.

These indexes cover most investable U.S. equities and serve as key benchmarks, with about $11.8 trillion in assets benchmarked to Russell U.S. Indexes as of December 31, 2024.

Positive

• Added to Russell 3000, Russell 1000, Russell 2500 and Russell Midcap indexes
• Index inclusion effective at close of U.S. equity markets on June 26, 2026
• Automatic inclusion in corresponding Russell growth and value style indexes
• Exposure to benchmarks tied to about $11.8 trillion in Russell-indexed assets

Negative

• None.

News Market Reaction – ASND

+1.13%

+1.13% Session close to close

In the Jun 29 session, ASND gained 1.13%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement increases visibility by adding Ascendis to multiple Russell benchmarks that underl...

Analysis

This announcement increases visibility by adding Ascendis to multiple Russell benchmarks that underlie $11.8 trillion in benchmarked assets. Investors may watch how index-linked demand interacts with its recent positive news flow and relatively low short positioning.

Key Figures

Russell 3000 coverage: 3,000 U.S. stocks U.S. equity coverage: 98% of investable U.S. equities Russell 1000 size: 1,000 largest securities +5 more

8 metrics

Russell 3000 coverage 3,000 U.S. stocks Constituents tracked in Russell 3000 Index

U.S. equity coverage 98% of investable U.S. equities Portion represented by Russell 3000 by market cap

Russell 1000 size 1,000 largest securities Large-cap segment within Russell 3000

Large-cap coverage more than 90% of investable U.S. equities Covered by Russell 1000 Index

Russell 2500 size 2,500 smallest securities Small-to-mid-cap segment within Russell 3000

Russell Midcap size 800 smallest companies Constituents within the Russell 1000 Index

Benchmarked assets $11.8 trillion Assets benchmarked to Russell U.S. Indexes as of Dec 31, 2024

Effective date June 26, 2026 Effective at close of U.S. markets for index inclusion

Historical Context

5 past events · Latest: 2026-06-13 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
2026-06-13	Phase 3 trial data	Positive	+2.4%	Long-term Phase 3 PaTHway data showed sustained efficacy and safety in hypoparathyroidism.
2026-06-11	Phase 2 trial data	Positive	+2.5%	Five-year Phase 2 PaTH Forward data showed durable efficacy and kidney function benefits.
2026-06-08	Conference presentations	Positive	+2.9%	Company highlighted multiple rare endocrine programs and late-stage data at ENDO 2026.
2026-05-07	Quarterly earnings	Positive	+4.3%	Q1 2026 results showed strong product revenues and positive net profit metrics.
2026-05-06	Pivotal trial results	Positive	+4.3%	Two-year ApproaCH trial data showed pronounced growth gains in children with achondroplasia.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive clinical and earnings updates have consistently aligned with positive next-day price reactions.

Key Terms

russell 3000® index, russell 1000® index, russell 2500® index, russell midcap® index, +2 more

6 terms

russell 3000® index financial

"added to the broad-market Russell 3000® Index, the large-cap Russell 1000®"

A broad stock market index that tracks the performance of about 3,000 publicly traded U.S. companies of all sizes, acting as a wide-ranging snapshot of the U.S. equity market. It matters to investors because it serves as a common yardstick for the overall market’s health and is the basis for many index funds and investment strategies—think of it as a single basket that shows how the whole U.S. stock market is doing.

russell 1000® index financial

"the large-cap Russell 1000® Index, the small-to-mid-cap Russell 2500® Index"

A stock market index that tracks the performance of the 1,000 largest publicly traded U.S. companies by market value, the Russell 1000® gives a snapshot of how big-cap and many mid-cap businesses are doing as a group. For investors it matters because the index acts like a large shopping cart of major stocks—used as a benchmark for fund performance, a basis for index funds and ETFs, and a quick gauge of broad market health and investor risk exposure.

russell 2500® index financial

"the small-to-mid-cap Russell 2500® Index, and the Russell Midcap® Index"

A market index that tracks the combined performance of a broad group of U.S. small- and mid-sized publicly traded companies, offering a snapshot of how that portion of the market is doing. Investors use it like a thermometer for the smaller-company segment—helpful for benchmarking fund performance, gauging risk and growth trends, and deciding whether to tilt a portfolio toward smaller, typically faster-growing but more volatile firms.

russell midcap® index financial

"Russell 2500® Index, and the Russell Midcap® Index as a part of the 2026"

The Russell Midcap® Index is a market index that measures the performance of a broad group of medium-sized U.S. publicly traded companies, selected by size and trading activity. Investors use it like a thermometer to see how the mid-sized segment of the market is doing, to compare fund performance, or to track investments in exchange-traded funds and mutual funds; midcap firms often offer a mix of growth potential and relative stability, so movements in the index can signal shifts in risk and opportunity.

semi-annual reconstitution financial

"Russell Midcap® Index as a part of the 2026 Russell U.S. Indexes semi-annual reconstitution"

A semi-annual reconstitution is the twice-yearly review and reset of a market index’s list of included securities and their weights. Think of it like updating the roster on a sports team: some players are added, others removed, and positions are rebalanced; the change matters to investors because index-tracking funds and many portfolios must buy or sell shares to match the new lineup, which can move stock prices and affect trading volume and portfolio performance.

index funds financial

"used by investment managers and institutional investors as the basis for index funds"

A fund that pools investors’ money to buy the same collection of stocks or bonds that make up a market index — like a ready-made basket representing the whole market or a specific slice of it. It matters because it gives broad exposure with lower fees and simpler management than picking individual securities, reducing the impact of any single holding and making it efficient for long-term investing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company has been added to the broad-market Russell 3000^® Index, the large-cap Russell 1000^® Index, the small-to-mid-cap Russell 2500^® Index, and the Russell Midcap^® Index as a part of the 2026 Russell U.S. Indexes semi-annual reconstitution, effective at the close of U.S. equity markets on June 26, 2026.

The Russell 3000^® Index tracks the largest 3,000 U.S. stocks, representing approximately 98% of investable U.S. equities by market capitalization. Within the Russell 3000^®, the Russell 1000^® Index comprises the 1,000 largest securities, representing more than 90% of investable U.S. equities; the Russell 2500^® Index comprises the 2,500 smallest securities, spanning the small-to-mid-cap segment; and the Russell Midcap^® Index comprises the 800 smallest companies within the Russell 1000^®. Inclusion in the Russell 1000^®, Russell 2500^®, and Russell Midcap^® Indexes results in automatic inclusion in the appropriate growth and value style indexes.

Russell U.S. Indexes are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for active investment strategies. According to market data as of December 31, 2024, approximately $11.8 trillion in assets are benchmarked against Russell U.S. Indexes.

For more information on the Russell Indexes and the semi-annual reconstitution process, please visit the “Russell Reconstitution” section of the FTSE Russell website.

About Ascendis Pharma A/S
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference for patients, and (ii) Ascendis’ ability to apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including, without limitation: dependence on third‑party manufacturers, distributors, and service providers for Ascendis’ products and product candidates; risks related to regulatory review and approval, including the possibility of delays, requests for additional data or analyses, restrictions or limitations on use, approval with labeling that is more limited than expected, or failure to obtain approval in the United States, European Union, or other jurisdictions; clinical development risks, including that results from ongoing or future trials may not confirm earlier data; unforeseen safety or efficacy findings in development programs or on‑market products; manufacturing, supply chain, quality, or logistics issues that could delay development or commercialization; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen research and development or selling, general and administrative expenses and other costs impacting Ascendis’ business generally; market acceptance, pricing, and reimbursement challenges, including payer coverage decisions and health technology assessments; competitive developments, including new or improved therapies; intellectual property protection, freedom‑to‑operate, and litigation risks; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; cybersecurity, data privacy, and information technology disruptions; and the impact of international economic, political, legal, compliance, public health, and business factors, including tariffs, trade policies, currency fluctuations, and geopolitical events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 11, 2026, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, and TransCon are trademarks owned by the Ascendis Pharma group. © June 2026 Ascendis Pharma A/S.

Investor Contact:	Media Contact:
Chad Fugere	Melinda Baker
Ascendis Pharma	Ascendis Pharma
+1 (650) 519-7494	+1 (650) 709-8875

FAQ

What Russell indexes did Ascendis (ASND) join on June 26, 2026?

Ascendis was added to the Russell 3000, Russell 1000, Russell 2500 and Russell Midcap indexes. According to Ascendis, this followed the 2026 Russell U.S. Indexes semi-annual reconstitution, effective after the U.S. equity market close on June 26, 2026.

When did Ascendis (ASND) inclusion in the Russell U.S. indexes become effective?

Ascendis index inclusion became effective at the close of U.S. equity markets on June 26, 2026. According to Ascendis, this timing aligns with the 2026 Russell U.S. Indexes semi-annual reconstitution schedule across the affected benchmarks.

How does joining the Russell 3000 and Russell 1000 affect Ascendis (ASND)?

Joining the Russell 3000 and Russell 1000 places Ascendis within widely followed U.S. equity benchmarks. According to Ascendis, these indexes track the largest U.S. stocks by market cap and underpin many index funds and institutional strategies.

What is the significance of Ascendis (ASND) entering the Russell Midcap and Russell 2500?

Ascendis entry into the Russell Midcap and Russell 2500 associates the stock with defined small-to-mid-cap and midcap segments. According to Ascendis, these memberships also trigger automatic inclusion in related growth and value style indexes.

How much investor capital is benchmarked to Russell U.S. indexes that now include Ascendis (ASND)?

Approximately $11.8 trillion in assets were benchmarked against Russell U.S. indexes as of December 31, 2024. According to Ascendis, these benchmarks, which now include the company, are widely used by investment managers and institutional investors.